Key result
Indobufen markedly inhibits exercise-induced platelet malondialdehyde and serotonin release versus placebo in stable angina.
Why the study?
Does a single oral 200 mg dose of indobufen inhibit platelet activation during exercise in patients with stable angina?
RCT (n=20)
Double-blind
Does a single oral 200 mg dose of indobufen inhibit platelet activation during exercise in patients with stable angina?
Indobufen inhibits exercise-induced platelet activation and prostaglandin pathway activation in patients with stable angina.
Answers are grounded in this paper and cite their sources.
Supports indobufen to blunt exercise-induced platelet activation in stable angina; extends prior antiplatelet data to exertional conditions.
Platelet 14C-serotonin release induced by collagen, and platelet malondialdehyde (M.D.A.) generation induced by thrombin were assessed in twenty patients with stable angina, before and after exercise with a bicycle ergometer. The patients received a single oral 200 mg dose of indobufen or placebo according to a crossover design in double-blind conditions. The M.D.A. concentration increased when exercise was carried out after placebo, whereas indobufen markedly inhibited M.D.A. production and 14C-serotonin release. These results suggest that effort may be an important factor in activation of the platelet prostaglandin pathway and that the use of antithrombotic drugs may be appropriate in patients with angina.
No takes yet. Share an insight, caveat, or question.
Pogliani et al. (1983) conducted an RCT in stable angina (n=20). Indobufen vs. Placebo was evaluated on Platelet 14C-serotonin release and platelet malondialdehyde (M.D.A.) generation. A single dose of indobufen markedly inhibited exercise-induced platelet malondialdehyde production and 14C-serotonin release compared to placebo in patients with stable angina.
Synapse has enriched 10 related papers. Consider them for comparative context: